ATE222769T1 - Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens - Google Patents

Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens

Info

Publication number
ATE222769T1
ATE222769T1 AT97930090T AT97930090T ATE222769T1 AT E222769 T1 ATE222769 T1 AT E222769T1 AT 97930090 T AT97930090 T AT 97930090T AT 97930090 T AT97930090 T AT 97930090T AT E222769 T1 ATE222769 T1 AT E222769T1
Authority
AT
Austria
Prior art keywords
csf
administration
recurrence
prevent
brain tumors
Prior art date
Application number
AT97930090T
Other languages
English (en)
Inventor
Walter C Low
Margaret A Wallenfriedman
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE222769T1 publication Critical patent/ATE222769T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
AT97930090T 1996-06-27 1997-06-18 Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens ATE222769T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/671,251 US5837231A (en) 1996-06-27 1996-06-27 GM-CSF administration for the treatment and prevention of recurrence of brain tumors
PCT/US1997/010540 WO1997049421A1 (en) 1996-06-27 1997-06-18 Gm-csf administration for the treatment and prevention of recurrence of brain tumors

Publications (1)

Publication Number Publication Date
ATE222769T1 true ATE222769T1 (de) 2002-09-15

Family

ID=24693739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930090T ATE222769T1 (de) 1996-06-27 1997-06-18 Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens

Country Status (9)

Country Link
US (1) US5837231A (de)
EP (1) EP0912192B1 (de)
JP (1) JP2000515127A (de)
AT (1) ATE222769T1 (de)
AU (1) AU3400297A (de)
CA (1) CA2258608A1 (de)
DE (1) DE69715000T2 (de)
DK (1) DK0912192T3 (de)
WO (1) WO1997049421A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
AU1628599A (en) * 1997-12-05 1999-06-28 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan
JP5546084B2 (ja) * 1998-05-26 2014-07-09 オプサニテクス エルエルシー 抗原に対する免疫応答を調節する組成物および方法
AU5458500A (en) * 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
ATE371017T1 (de) * 2000-09-15 2007-09-15 Ortho Mcneil Pharm Inc Zusammensetzungen und verfahren zur auslösung spezifischer zytolytischer t-zellantworten
CA2441434A1 (en) * 2001-03-12 2002-09-19 Institute Of Gene And Brain Science Remedies for nerve damages
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007081878A2 (en) * 2006-01-07 2007-07-19 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
CA2661042C (en) 2006-08-18 2012-12-11 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
JP5901877B2 (ja) * 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
WO2011044542A1 (en) 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
JP6426001B2 (ja) * 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
WO2013078392A1 (en) * 2011-11-21 2013-05-30 The University Of Chicago Methods and compositions involving induced senescent cells for cancer treatment
EP2785378B1 (de) 2011-12-02 2020-05-13 Armagen, Inc. Verfahren und zusammensetzungen für erhöhte sulfatase-a-aktivität im zns
PT3536334T (pt) 2012-05-16 2021-09-27 Stemline Therapeutics Inc Vacinas contra o cancro dirigidas a células estaminais cancerígenas
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5208022A (en) * 1988-05-19 1993-05-04 State University Of New York (Suny) Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens

Also Published As

Publication number Publication date
EP0912192A1 (de) 1999-05-06
DK0912192T3 (da) 2002-12-02
DE69715000T2 (de) 2003-01-02
US5837231A (en) 1998-11-17
CA2258608A1 (en) 1997-12-31
DE69715000D1 (de) 2002-10-02
WO1997049421A1 (en) 1997-12-31
JP2000515127A (ja) 2000-11-14
AU3400297A (en) 1998-01-14
EP0912192B1 (de) 2002-08-28

Similar Documents

Publication Publication Date Title
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
DK0585943T3 (da) Opløselige ligander for CD40
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ES8801546A1 (es) Un procedimiento para la preparacion de compuesto de 2,2-difluoronucleosidos.
DE69703649D1 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
NO974275D0 (no) Fremgangsmåte for behandling av tumorer
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69519937D1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
ATE90563T1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
MY105075A (en) Cancer treatment
UA22037A (uk) Спосіб лікуваhhя виразкової хвороби шлуhка та дваhадцятипалої кишки
ATE237697T1 (de) Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit
ATE49965T1 (de) Verwendung von 2-beta-d-ribofuranosylthiazol-4carboxamiden zur herstellung von medikamenten zur behandlung von krebsartigen tumoren.
DE58904510D1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.
ATE89727T1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties